Screening Platform for Clinical Trials in Advanced Colorectal Cancer
- Conditions
- Colorectal CancerAdvanced Colorectal Cancer
- Interventions
- Genetic: Tumour markers testing
- Registration Number
- NCT01723969
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Brief Summary
The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials.
Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients.
A major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients.
The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 668
- Colo-rectal cancer (advanced or metastatic)
- Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
- Absence of patient's consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Colo-rectal cancer Tumour markers testing Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
- Primary Outcome Measures
Name Time Method Tumour markers assessment Within 1 week after patient registration Five basic tumour markers will be tested: Kras, nras, braf, MSI and PKI3
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (27)
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme
馃嚙馃嚜Brussels, Belgium
Cliniques Universitaires Saint-Luc
馃嚙馃嚜Brussels, Belgium
Universitair Ziekenhuis Antwerpen
馃嚙馃嚜Edegem, Belgium
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet
馃嚙馃嚜Brussels, Belgium
The Great Poland Cancer Centre
馃嚨馃嚤Poznan, Poland
Bank Of Cyprus Oncology Centre
馃嚚馃嚲Str贸volos, Cyprus
Universitaetsklinikum Carl Gustav Carus
馃嚛馃嚜Dresden, Germany
Universitaets-Krankenhaus Eppendorf
馃嚛馃嚜Hamburg, Germany
Kliniken Oldenburg
馃嚛馃嚜Oldenburg, Germany
IRCCS Azienda Ospedaliera Universitaria San Martino "IST" Istituto Nazionale per la Ricerca sul Cancro
馃嚠馃嚬Genova, Italy
H么pitaux universitaires de Gen猫ve - HUG - site de Cluse-Roseraie
馃嚚馃嚟Geneva, Switzerland
Hopital du Valais - Hopital de Sion
馃嚚馃嚟Sion, Switzerland
Maria Sklodowska-Curie Memorial Cancer Centre
馃嚨馃嚤Warsaw, Poland
Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals
馃嚜馃嚫L'Hospitalet de Llobregat, Spain
Hospital Universitario San Carlos
馃嚜馃嚫Madrid, Spain
Centre Hospitalier Universitaire Vaudois
馃嚚馃嚟Lausanne, Switzerland
UniversitaetsSpital Zurich
馃嚚馃嚟Zurich, Switzerland
U.Z. Leuven - Campus Gasthuisberg
馃嚙馃嚜Leuven, Belgium
Gustave Roussy Cancer Campus
馃嚝馃嚪Villejuif, France
Universitaetsklinikum Leipzig
馃嚛馃嚜Leipzig, Germany
Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern
馃嚛馃嚜Muenchen, Germany
University General Hospital Heraklion
馃嚞馃嚪Heraklion, Greece
Seconda Universita Degli Studi Di Napoli
馃嚠馃嚬Napoli, Italy
I.P.O. Francisco Gentil - Centro De Lisboa
馃嚨馃嚬Lisboa, Portugal
Ostra Sjukhuset
馃嚫馃嚜Goteborg, Sweden
Hospital Universitario 12 De Octubre
馃嚜馃嚫Madrid, Spain
Hospital General Vall D'Hebron
馃嚜馃嚫Barcelona, Spain